Quick Answer
MEDICINOVA INC reported Total Revenue of $409.7 thousand for fiscal year 2025.
MEDICINOVA INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $409.7K | — | $1.00M | — | $4.04M | — |
| Revenue (ASC 606) | $409.7K | — | $1.00M | — | $4.04M | — |
| Net Income | -$12.00M -8.6% |
-$11.05M -28.9% |
-$8.57M +39.1% |
-$14.07M -38.8% |
-$10.13M +26.8% |
-$13.85M -7.0% |
| Diluted EPS | -$0.24 -4.3% |
-$0.23 -35.3% |
-$0.17 +41.4% |
-$0.29 -38.1% |
-$0.21 | — |
| Total Assets | $45.60M -18.4% |
$55.88M -15.7% |
$66.27M -10.6% |
$74.15M -15.2% |
$87.41M +15.9% |
$75.42M -4.8% |
| Cash and Equivalents | $30.81M -23.7% |
$40.36M -20.9% |
$51.00M +175.6% |
$18.51M -74.1% |
$71.43M +19.0% |
$60.04M -5.9% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $41.59M -20.8% |
$52.50M -15.8% |
$62.38M -11.2% |
$70.24M -16.1% |
$83.68M +17.3% |
$71.33M -4.8% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$13.28M -4.8% |
-$12.68M -28.0% |
-$9.90M +32.3% |
-$14.63M -43.2% |
-$10.22M +27.9% |
-$14.18M -1.0% |
| Shares Outstanding | 49.22M +0.4% |
49.05M +0.0% |
49.05M +0.0% |
49.05M +0.0% |
49.04M +8.9% |
45.02M +2.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $123.3K | — | -8.4% |
| Revenue (ASC 606) | September 30, 2025 | $123.3K | — | -8.4% |
| Net Income | September 30, 2025 | -$3.05M | -6.9% | +7.0% |
| Diluted EPS | September 30, 2025 | -$0.06 | +0.0% | +14.3% |
| Total Assets | September 30, 2025 | $47.58M | -18.1% | -4.5% |
| Cash and Equivalents | September 30, 2025 | $32.56M | -23.0% | -5.0% |
| Long-Term Debt | September 30, 2011 | $0.00 | — | — |
| Stockholders Equity | September 30, 2025 | $43.96M | -20.2% | -6.2% |
| R&D Expense | September 30, 2013 | $785.6K | -10.0% | -17.0% |
| Operating Income | September 30, 2025 | -$3.38M | -2.2% | +6.3% |
| Shares Outstanding | September 30, 2025 | 49.05M | +0.0% | +0.0% |
- MEDICINOVA INC reported Total Revenue of $409.7 thousand for fiscal year 2025.
- MEDICINOVA INC showed a decrease of -59.0% in Total Revenue compared to the prior fiscal year.
- MEDICINOVA INC reported Revenue (ASC 606) of $409.7 thousand for fiscal year 2025.
- MEDICINOVA INC showed a decrease of -59.0% in Revenue (ASC 606) compared to the prior fiscal year.
- MEDICINOVA INC reported Net Income of -$12.00 million for fiscal year 2025.
- MEDICINOVA INC showed a decrease of -8.6% in Net Income compared to the prior fiscal year.
- MEDICINOVA INC reported Diluted EPS of $0.24 per share (loss) for fiscal year 2025.
- MEDICINOVA INC showed a decrease of -4.3% in Diluted EPS compared to the prior fiscal year.
- MEDICINOVA INC reported Total Assets of $45.60 million for fiscal year 2025.
- MEDICINOVA INC showed a decrease of -18.4% in Total Assets compared to the prior fiscal year.
- MEDICINOVA INC reported Cash and Equivalents of $30.81 million for fiscal year 2025.
- MEDICINOVA INC showed a decrease of -23.7% in Cash and Equivalents compared to the prior fiscal year.
- MEDICINOVA INC reported Long-Term Debt of $9.48 million for fiscal year 2010.
- MEDICINOVA INC reported Stockholders Equity of $41.59 million for fiscal year 2025.
- MEDICINOVA INC showed a decrease of -20.8% in Stockholders Equity compared to the prior fiscal year.
- MEDICINOVA INC reported R&D Expense of $5.01 million for fiscal year 2012.
- MEDICINOVA INC showed a decrease of -35.6% in R&D Expense compared to the prior fiscal year.
- MEDICINOVA INC reported Operating Income of -$13.28 million for fiscal year 2025.
- MEDICINOVA INC showed a decrease of -4.8% in Operating Income compared to the prior fiscal year.
- MEDICINOVA INC reported Shares Outstanding of 49.22 million shares for fiscal year 2025.
- MEDICINOVA INC showed an increase of +0.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: